Pubblicità
Pubblicità
di Giancarlo Nicoli
Sep
24
Stereotaxis Showcases Interventional Value of Magnetic Navigation at TCT 2009
Filed Under Stereotaxis | Leave a Comment
Stereotaxis Showcases Interventional Value of Magnetic Navigation at TCT 2009
ST. LOUIS, Sept. 24 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS) is showcasing the value of its technologies for interventional procedures at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Francisco this week. Stereotaxis pioneered remote magnetic navigation in electrophysiology and clinicians have repeatedly demonstrated the value of its technologies in the treatment of cardiac arrhythmias. More than 23,000 cases have been performed with the Magnetic Navigation System, and this clinical experience includes many compelling interventional procedures. In the cath lab as well as the EP lab, Stereotaxis’ computer-controlled devices, integrated information systems and advanced networking tools deliver opportunities for hospitals and clinicians to simplify the treatment of complex cases and ultimately aim for enhanced patient care and improved outcomes.
On Monday, September 21, Dr. Gurpreet S. Sandhu of the Mayo Clinic presented data from his use of Stereotaxis’ Magnetic Navigation System to treat chronic total occlusions. In his presentation “Beyond Guidewires: What Novel Technologies Help Today?” Dr. Sandhu highlighted the value of the Niobe system in the treatment of failed PCIs . Additionally, Dr. Jeffrey Moses of Columbia University Medical Center presented a live case in which he used the Stereotaxis three-dimensional vessel reconstruction to assist in the treatment of a chronic total occlusion in a patient who had previously undergone open heart surgery.
“Our Niobe System has been used to perform more procedures across the broadest range of cardiovascular applications than any other remote magnetic, robotic or mechanical navigation system presently available,” said Michael P. Kaminski, Stereotaxis President and CEO. “In addition to its widespread adoption in EP labs, the Niobe System has been used in the treatment of patients with congenital heart defects and peripheral vascular occlusive disease, and we are very excited about the opportunities we see to extend the value of our magnetic navigation and information management technologies into these and other potential cardio-vascular applications.”
At its TCT booth #600, Stereotaxis is showcasing its Pegasus(TM) Magnetic Guidewires and Odyssey(TM) System.
Pegasus Magnetic Guidewires
Stereotaxis recently introduced the Pegasus family of magnetically steerable guidewires. Pegasus is a blended stainless steel and Nitinol(TM) wire that provides exceptional and accurate omni-directional distal tip control. Its clinical advantages include excellent torque control and tip durability; optimal shaft support and device deliverability; and nearly effortless advancement through stenotic and tortuous vessel segments.
The Odyssey System
The Odyssey information backbone will be showcased by demonstrating the new Odyssey QuadHD ultra high resolution display and Odyssey Cinema, which synchronizes and archives lab data and can share a fully integrated view of a procedure with any laptop in the world on a high speed internet connection. This Odyssey portfolio is now designed to integrate standard labs, allowing all labs within a department to leverage the capabilities of remote lab viewing, recording and collaboration.
TCT is being held at the Moscone Center in San Francisco from September 21 to 25, 2009. For more information on Stereotaxis, please visit www.stereotaxis.com.
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.
About Forward Looking Statements
This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
SOURCE: Stereotaxis, Inc.
di Giancarlo Nicoli
Sep
16
Stop alle lampade abbronzanti, sono cancerogene
Filed Under Il mestiere di farmacista, Stili di vita | Leave a Comment
L´Agenzia internazionale per la ricerca sul cancro certifica che i lettini agli ultravioletti sono cancerogeni, senza dubbio. La ricerca uscirà sul numero di agosto di The Lancet Oncology. Ne dà notizia la Repubblica.
«Le lampade abbronzanti – scrive Repubblica – fanno un salto nella classificazione dei fattori di rischio per il tumore. Dalla seconda categoria “probabilmente cancerogeno” passano alla prima “cancerogeno” tout court. La decisione è stata presa dall’Agenzia internazionale per la ricerca sul cancro, che fa parte dell’Organizzazione mondiale per la sanità».
«La nostra analisi ha concluso – scrive il gruppo di 20 esperti basato a Lione e guidato da Fatiha al Ghissassi – che l´esposizione ai raggi ultravioletti artificiali prima dei trent´anni di età fa aumentare il rischio di melanoma del 75%. Il melanoma è il più aggressivo fra i tumori della pelle e se una cinquantina d´anni fa era considerato malattia piuttosto rara, oggi in Italia la sua incidenza aumenta al ritmo del 4-8% all’anno. A livello mondiale, si calcola che i casi di questo tumore siano raddoppiati negli ultimi dieci anni».
«Inoltre – mette in guardia l´Agenzia di Lione – l´abbronzatura artificiale è anche legata al maggior rischio di malattie degli occhi. Cataratta e infiammazioni della cornea in primis. La Germania, alcuni stati degli Usa e dell´Australia hanno vietato l´uso dei lettini solari ai minorenni. Anche il governo inglese sta studiando una misura analoga. In Italia invece la foresta delle circa 40 mila lampade abbronzanti, distribuite in 13 mila centri estetici, resta ancora poco regolamentata».
Fonte:
La Repubblica, 29 luglio 2009, pag. 17
di Giancarlo Nicoli
Sep
15
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center Orders 4 Odyssey Systems
Filed Under Stereotaxis | Leave a Comment
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center Orders 4 Odyssey Systems
Largest Single Odyssey Order to Date
ST. LOUIS, Sept. 15 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq: STXS), announced that the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas ordered four Odyssey(TM) systems. One will manage its Niobe((R)) Remote Magnetic Navigation electrophysiology lab and the other three will manage its standard, non-Niobe EP labs. All four systems will utilize an Odyssey Cinema server to record synchronized procedure data and share this information via the Internet anywhere in the world.
Odyssey Cinema synchronizes the data from multiple interventional lab systems and includes a powerful archiving capability to instantly store and replay an integrated view of entire procedures or segments of procedures. The solution also allows physicians to collaborate with high-definition views of live or recorded procedures from multiple points in the network of installed Odyssey systems, providing a significant new tool for clinical collaboration, remote consultation, and educational training. There are currently more than 60 Odyssey systems ordered to date.
“Our vision is to use Odyssey to significantly accelerate the advancement of electrophysiology worldwide,” said Andrea Natale, M.D., F.A.C.C., F.H.R.S., and Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. “With Odyssey, we have the technology to create unprecedented educational programs by sharing live cases over the network and by replaying best practices in interactive forums. Our connection to other centers on the Odyssey network will allow us to collaborate from Austin with other experts on a global basis without traveling. This creates a new standard for the practice of electrophysiology, unleashing new opportunities by allowing hospitals to have a powerful marketing tool and enabling patients on the Odyssey network to receive enhanced care around the world.”
The Texas Cardiac Arrhythmia Institute at St. David’s Medical Center will utilize the Odyssey network to connect with specific facilities around the world. Deliveries of the Odyssey systems to manage the standard EP labs will begin in the fourth quarter.
“This is the largest Odyssey order to date, and we are particularly excited by this opportunity to transform the EP department at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center,” said Michael P. Kaminski, Stereotaxis President and CEO. “We developed Odyssey to standardize data integration and management for all interventional labs and provide access to the live and recorded procedure information where and when it is needed. Through its proprietary data compression technology, the system enables sharing of this data with other interventional labs around the world via a secure Internet connection. With its unique capabilities, we anticipate that the Odyssey network will continue to establish a forum for defining clinical best practices across a broad spectrum of medical procedures.”
About Odyssey
The Odyssey portfolio of products provides an innovative information backbone for managing, controlling, recording and sharing procedures performed in interventional labs. The Odyssey Workstation standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Through its proprietary data compression technology, the Odyssey enables the sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection. Hospitals can also share procedures with other institutions using Odyssey Connect providing a forum for defining clinical best practices across a broad spectrum of medical procedures.
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.
About Forward Looking Statements
This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
SOURCE: Stereotaxis, Inc.
Pubblicità
Creative Common License
